Aldeyra Therapeutics (NASDAQ:ALDX – Get Rating) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.02, MarketWatch Earnings reports. During the same period in the previous year, the firm earned ($0.25) EPS.
NASDAQ ALDX traded down $0.07 on Friday, hitting $2.71. The company had a trading volume of 1,000,556 shares, compared to its average volume of 689,788. The company’s fifty day moving average price is $4.15 and its 200-day moving average price is $5.21. The company has a debt-to-equity ratio of 0.08, a current ratio of 19.77 and a quick ratio of 19.77. Aldeyra Therapeutics has a 12-month low of $2.65 and a 12-month high of $13.18.
ALDX has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Aldeyra Therapeutics in a research report on Wednesday, April 27th. StockNews.com initiated coverage on Aldeyra Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating for the company. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.00.
About Aldeyra Therapeutics (Get Rating)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
- Get a free copy of the StockNews.com research report on Aldeyra Therapeutics (ALDX)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.